Xanthine oxidoreductase (XoR) inhibitor administration reduces uric acid and reactive oxygen species (RoS) production, and also lowers blood pressure (Bp). However, the associations of plasma XoR activity, uric acid level, and oxidative stress levels with Bp remain unclear. this cross-sectional study included 156 subjects (68 males, 88 females) registered in the MedCity21 health examination registry without anti-hypertensive or anti-hyperuricemic agent administration. plasma XoR activity was measured using our highly sensitive novel assay, which is unaffected by uric acid in the sample. Bp was also determined, and serum uric acid and derivative of reactive oxygen metabolites (d-RoMs) levels were simultaneously measured. Median plasma XoR activity, serum uric acid, d-RoMs, and mean arterial pressure (MAP) values were 25.7 pmol/h/mL, 5.4 mg/dL, 305 Carr U, and 89.0 mmHg, respectively. Multiple regression analysis showed that plasma XoR activity (β = 0.211, p = 0.019), but not serum uric acid (β = 0.072, p = 0.502), was significantly associated with MAP. In subjects with lower but not higher d-RoMs level, an independent association of plasma XoR activity with MAp was observed (β = 0.428, p = 0.001 and β = 0.019, p = 0.891, respectively; p for interaction = 0.046). XoR may contribute to the pathophysiology of higher Bp through RoS but not uric acid production, especially in patients with lower oxidative stress.